advertisement

Oculus

Classification List

  • 1 General aspects0
  • 1.1 Epidemiology0
  • 1.2 Population genetics0
  • 1.3 Pathogenesis0
  • 1.4 Quality of life0
  • 1.5 Glaucomas as cause of blindness0
  • 1.6 Prevention and screening0
  • 2 Anatomical structures in glaucoma0
  • 2.1 Conjunctiva0
  • 2.2 Cornea0
  • 2.3 Sclera0
  • 2.4 Anterior chamber angle0
  • 2.5 Meshwork0
  • 2.5.1 Trabecular meshwork0
  • 2.5.2 Schlemms canal0
  • 2.5.3 Scleral outlet channels0
  • 2.6 Aqueous humor dynamics0
  • 2.6.1 Production0
  • 2.6.2 Outflow0
  • 2.6.2.1 Trabecular meshwork0
  • 2.6.2.2 Uveoscleral0
  • 2.6.3 Compostion0
  • 2.7 Episcleral veins and venous pressure0
  • 2.8 Iris0
  • 2.9 Ciliary body0
  • 2.10 Lens0
  • 2.11 Vitreous body0
  • 2.12 Choroid, peripapillary choroid, peripapillary atrophy0
  • 2.13 Retina and retinal nerve fibre layer0
  • 2.14 Optic disc0
  • 2.15 Optic nerve0
  • 2.16 Chiasma and retrochiasmal central nervous system0
  • 2.17 Stem cells0
  • 2.20 Other0
  • 3 Laboratory methods0
  • 3.1 Microscopy0
  • 3.2 Electron microscopy0
  • 3.3 Immunohistochemistry0
  • 3.4 Molecular genetics0
  • 3.4.1 Linkage studies0
  • 3.4.2 Gene studies0
  • 3.5 Molecular biology incl. SiRNA0
  • 3.6 Cellular biology0
  • 3.7 Biochemistry0
  • 3.8 Pharmacology0
  • 3.9 Pathophysiology0
  • 3.10 Immunobiology0
  • 3.11 Pharmacogenetics0
  • 3.12 Proteomics0
  • 3.13 In vivo imaging0
  • 3.13.1 Laser Scanning0
  • 3.13.1.1 Confocal Scanning Laser Ophthalmoscopy0
  • 3.13.1.2 Confocal Scanning Laser Polarimetry0
  • 3.13.2 Optical Coherence Tomography0
  • 3.13.2.1 Anterior Segment0
  • 3.13.2.2 Posterior Segment0
  • 3.13.3 RGC Imaging0
  • 3.13.4 Other0
  • 3.20 Other0
  • 4 Tissue culture of ocular cells0
  • 5 Experimental glaucoma; animal models0
  • 5.1 Rodent0
  • 5.2 Primates0
  • 5.3 Other0
  • 6 Clinical examination methods0
  • 6.1 Intraocular pressure measurement; factors affecting IOP0
  • 6.1.1 Devices, techniques0
  • 6.1.2 Fluctuation, circadian rhythms0
  • 6.1.3 Factors affecting IOP0
  • 6.2 Tonography, aqueous flow measurement (see also 2.6)0
  • 6.3 Biomicroscopy (slitlamp)0
  • 6.3.1 Anterior segment0
  • 6.3.2 Posterior segment0
  • 6.4 Gonioscopy0
  • 6.5 Ophthalmoscopy0
  • 6.6 Visual field examination and other visual function tests0
  • 6.6.1 Conventional manual0
  • 6.6.2 Automated0
  • 6.6.3 Special methods (e.g. color, contrast, SWAP etc.)0
  • 6.7 Electro-ophthalmodiagnosis0
  • 6.8 Photography0
  • 6.8.1 Anterior segment0
  • 6.8.2 Posterior segment0
  • 6.9 Computerized image analysis0
  • 6.9.1 Laser scanning0
  • 6.9.1.1 Confocal Scanning Laser Ophthalmoscopy0
  • 6.9.1.2 Confocal Scanning Laser Polarimetry0
  • 6.9.2 Optical coherence tomography0
  • 6.9.2.1 Anterior0
  • 6.9.2.2 Posterior0
  • 6.9.5 Other0
  • 6.10 Fluorescein (ICG) angiography0
  • 6.10.1 Anterior segment0
  • 6.10.2 Posterior segment0
  • 6.11 Bloodflow measurements 0
  • 6.12 Ultrasonography and ultrasound biomicroscopy0
  • 6.13 Provocative tests0
  • 6.19 Telemedicine0
  • 6.20 Progression0
  • 6.30 Other0
  • 8 Refractive errors in relation to glaucoma0
  • 8.1 Myopia0
  • 8.2 Hypermetropia0
  • 8.3 Contact lenses0
  • 8.4 Refractive surgical procedures0
  • 8.5 Other0
  • 9 Clinical forms of glaucomas0
  • 9.1 Developmental glaucomas0
  • 9.1.1 Congenital glaucoma, Buphthalmos0
  • 9.1.2 Juvenile glaucoma0
  • 9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia0
  • 9.1.4 Other0
  • 9.2 Primary open angle glaucomas0
  • 9.2.1 Ocular hypertension0
  • 9.2.2 Other risk factors for glaucoma0
  • 9.2.3 Open angle glaucoma with elevated IOP0
  • 9.2.4 Normal pressure glaucoma0
  • 9.3 Primary angle closure glaucomas0
  • 9.3.1 Acute primary angle closure glaucoma (pupillary block)0
  • 9.3.2 Chronic primary angle closure glaucoma (pupillary block)0
  • 9.3.3 Plateau iris syndrome0
  • 9.3.4 Primary angle closure suspect0
  • 9.3.5 Primary angle closure0
  • 9.3.10 Other0
  • 9.4 Glaucomas associated with other ocular and systemic disorders0
  • 9.4.1 Steroid-induced glaucoma0
  • 9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera0
  • 9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy)0
  • 9.4.2.2 Posterior polymorphous dystrophy0
  • 9.4.2.3 Fuchs' endothelial dystrophy0
  • 9.4.2.5 Other0
  • 9.4.3 Glaucomas associated with disorders of the iris and ciliary body0
  • 9.4.3.1 Pigmentary glaucoma0
  • 9.4.3.5 Other0
  • 9.4.4 Glaucomas associated with disorders of the lens0
  • 9.4.4.1 Exfoliation syndrome0
  • 9.4.4.2 Glaucomas associated with cataracts0
  • 9.4.4.3 Glaucomas associated with lens dislocation0
  • 9.4.4.5 Other0
  • 9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous0
  • 9.4.5.1 Neovascular glaucoma0
  • 9.4.5.5 Other0
  • 9.4.6 Glaucomas associated with inflammation, uveitis 0
  • 9.4.7 Glaucomas associated with ocular trauma0
  • 9.4.8 Glaucomas associated with intraocular tumors0
  • 9.4.9 Glaucomas associated with elevated episcleral venous pressure0
  • 9.4.10 Glaucomas associated with hemorrhage0
  • 9.4.11 Glaucomas following intraocular surgery0
  • 9.4.11.1 Ciliary block (malignant) glaucoma0
  • 9.4.11.2 Glaucomas in aphakia and pseudophakia0
  • 9.4.11.3 Epithelial, fibrous, and endothelial proliferation0
  • 9.4.11.4 Glaucomas associated with corneal surgery0
  • 9.4.11.5 Glaucomas associated with vitreoretinal surgery0
  • 9.4.15 Glaucoma in relation to systemic disease0
  • 9.4.20 Other0
  • 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy0
  • 11 Medical treatment0
  • 11.1 General management, indication0
  • 11.2 Cholinergic drugs0
  • 11.3 Adrenergic drugs0
  • 11.3.1 Epinephrine0
  • 11.3.2 Thymoxamine, dapiprazole0
  • 11.3.3 Apraclonidine, brimonidine0
  • 11.3.4 Betablocker0
  • 11.3.5 Other0
  • 11.4 Prostaglandins0
  • 11.5 Carbonic anhydrase inhibitors0
  • 11.5.1 Systemic0
  • 11.5.2 Topical0
  • 11.6 Osmotic treatment0
  • 11.7 Treatment of bloodflow0
  • 11.8 Neuroprotection0
  • 11.9 Gene therapy0
  • 11.13 Combination therapy0
  • 11.13.1 Betablocker and pilocarpine0
  • 11.13.2 Betablocker and carbon anhydrase inhibitor0
  • 11.13.3 Betablocker and brimonidine0
  • 11.13.4 Betablocker and prostaglandin0
  • 11.13.5 Other0
  • 11.14 Investigational drugs; pharmacological experiments0
  • 11.15 Other drugs in relation to glaucoma0
  • 11.16 Vehicles, delivery systems, pharmacokinetics, formulation0
  • 11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence0
  • 11.20 Other0
  • 12 Surgical treatment0
  • 12.1 General management, indication0
  • 12.2 Laser iridotomy0
  • 12.3 Laser iridoplasty0
  • 12.4 Laser trabeculoplasty and other laser treatment of the angle0
  • 12.7 Surgical iridectomy0
  • 12.8 Filtering surgery0
  • 12.8.1 Without tube implant0
  • 12.8.2 With tube implant or other drainage devices0
  • 12.8.3 Non-perforating0
  • 12.8.4 Using laser0
  • 12.8.5 Other0
  • 12.8.10 Woundhealing antifibrosis0
  • 12.8.11 Complications, endophthalmitis0
  • 12.9 Trabeculotomy, goniotomy0
  • 12.10 Cyclodestruction0
  • 12.11 Cyclodialysis0
  • 12.12 Cataract extraction0
  • 12.12.1 Intracapsular0
  • 12.12.2 Extracapsular0
  • 12.12.3 Phacoemulsification0
  • 12.14 Combined cataract extraction and glaucoma surgery0
  • 12.14.1 Intracapsular0
  • 12.14.2 Extracapsular0
  • 12.14.3 Phacoemulsification0
  • 12.15 Capsulotomy0
  • 12.16 Vitrectomy0
  • 12.17 Anesthesia0
  • 12.20 Other 0
  • 13 Therapeutic prognosis and outcome0
  • 13.1 Prognostic factors0
  • 13.2 Outcome0
  • 13.2.1 IOP0
  • 13.2.2 Visual field0
  • 13.2.2.1 Progression0
  • 13.2.2.2 Improvement0
  • 13.2.3 Other0
  • 14 Costing studies; pharmacoeconomics0
  • 15 Miscellaneous1038

Issue 22-4

Change Issue


advertisement

WGA Rescources